WHO ICTRP trial
Drug trial in leprosy containing rifampicin, moxifloxacin and Clarithromycin…
CTRI/2024/03/064435 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2024/03/064435 |
|---|---|
| Public title | Drug trial in leprosy containing rifampicin , moxifloxacin and Clarithromycin versus routine MBMDT. |
| Scientific title | A comparative multicentric non inferiority clinical trial of WHO MBMDT with a new monthly chemotherapy regime containing Rifampicin, Moxifloxacin and Clarithromycin (RMC) on Multibacillary patients from India. - NIL |
| Primary sponsor | The leprosy mission Trust India |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 3 |
| Countries | India |
| Conditions | Health Condition 1: A304- Borderline lepromatous leprosy Health Condition 2: A302- Borderline tuberculoid leprosy Health Condition 3: A305- Lepromatous leprosy |
| Interventions | Intervention1: Once monthly RMC regime: Rifampicin 600 mg Moxifloxacin 500 mg Clarithromycin 1000 mg Once monthly for 12 months Control Intervention1: WHO MB MDT regime: Rifampicin 600 once monthly Clofazimine 300 once monthly Dapsone 100… |
| Registration date | Mar 19, 2024 |
| Target size | 280 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: